Clinical Trials on Recurrent Small-cell Lung Cancer (SCLC)

Total 8154 results

AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NSCLC (Non-small-cell Lung Cancer)

China
Palobiofarma SL
Novartis; H. Lee Moffitt Cancer Center and Research Institute

Completed

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO)

Non-small Cell Lung Cancer (NSCLC)

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States
National Cancer Institute (NCI)

Completed

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
Joseph J. Cullen, MD, FACS
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Recruiting

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (XACT-LUNG)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | NSCLC | Nonsmall Cell Lung Cancer | Non-Small-Cell Lung Carcinoma

United States
Amgen

Not yet recruiting

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (Eucalyptus)

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

China, Turkey, Australia, United States, Chile, Taiwan, Denmark, France, Spain, Argentina, Italy, Netherlands, Thailand, Korea, Republic of, Czechia, Portugal, Canada, United Kingdom
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
Samsung Medical Center
AstraZeneca

Completed

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) (BLOSSOM)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of
University Health Network, Toronto

Completed

Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT (SBRT FLT-PET)

Non Small Cell Lung Cancer (NSCLC)

Canada
Merck Sharp & Dohme LLC

Completed

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Non Small Cell Lung Cancer (NSCLC)
Maastricht Radiation Oncology
Anticancer Fund, Belgium; Reliable Cancer Therapies

Terminated

Nitroglycerin in Non-small Cell Lung Cancer (Nitroglycerin)

Non Small Cell Lung Cancer (NSCLC)

Netherlands
Tasly Pharmaceuticals, Inc.

Unknown

A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

China
Genzyme, a Sanofi Company

Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

United States, Czech Republic, Hungary
Radboud University Medical Center

Completed

Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

NSCLC | Locally Advanced Non-Small Cell Lung Cancer

Netherlands
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Tragara Pharmaceuticals, Inc.

Completed

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer (TP2001-201)

Recurrent Non Small Cell Lung Cancer

United States
Hebei Medical University Fourth Hospital

Recruiting

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

SCLC, Limited Stage

China
Peking University Cancer Hospital & Institute

Recruiting

Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance (MOSAIC)

SCLC,Extensive Stage

China
Tianjin Medical University Cancer Institute and...

Recruiting

Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer

SCLC, Extensive Stage

China
Peking Union Medical College

Recruiting

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, Recurrent

China
University of Kansas Medical Center
parkview cancer institute

Recruiting

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

NSCLC Stage IV | NSCLC, Recurrent

United States
Dwight Owen
Genentech, Inc.

Recruiting

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Metastatic Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States
Julia K. Rotow, MD
Inivata

Active, not recruiting

Plasma-Adapted First-Line Pembro In NSCLC

Metastatic Non-Small Cell Lung Cancer | NSCLC Stage IV

United States
Chao Huang
University of Kansas Medical Center

Active, not recruiting

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC)

United States
Washington University School of Medicine
Boston Scientific Corporation

Completed

EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States, Canada
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Bronchoalveolar Cell Lung Cancer

United States
Zai Lab (Shanghai) Co., Ltd.
Zai Lab (US) LLC

Recruiting

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer

SCLC

United States, China
Fox Chase Cancer Center
WindMIL Therapeutics

Withdrawn

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

NSCLC | SCLC
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Activating Mutation

United States
Hellenic Oncology Research Group

Completed

Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

SCLC

Greece
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Malignant Pleural Effusion

United States
Erin Bertino
Karyopharm Therapeutics Inc

Terminated

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Recurrent Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Malignant Pleural Effusion

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Memorial Sloan Kettering Cancer Center

Completed

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | EGFR Activating Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Translocation | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | ROS1 Gene Translocation

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

SCLC | Carcinoma, Small Cell

United Kingdom, United States
Vestre Viken Hospital Trust
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Recruiting

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)

Oncology | NSCLC Stage IV | NSCLC, Stage III

Norway
Ohio State University Comprehensive Cancer Center

Withdrawn

Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation

Fatigue | Cachexia | Radiation Toxicity | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Pulmonary Complications | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer
University Health Network, Toronto
OICR

Not yet recruiting

--SuPERIOR Trial--

Non-Small Cell Lung Cancer (NSCLC) | Clinical Staging T2b-3 N0-1 M0
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand, Brazil

Clinical Trials on Recurrent Small-cell Lung Cancer (SCLC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations